Chinese Hypertension Guidelines
Chinese Hypertension Guidelines
复制标题
DOI：
10.1159/000382025
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Jiguang Wang
中科院分区：
文献类型：
--
作者：
Jiguang Wang
根据2002年第四次全国营养与健康调查，中国高血压患病率为18.8%。虽然没有最近更新的全国性数据，但据信，在过去十年中，高血压的患病率大幅增加，在人口众多的中国，高血压患者超过2亿。为了应对高血压风险的增加，在过去的20年里，在1999年，2005年和2011年编制了三份中国高血压指南。目前的高血压管理指南文件名为“2010年中国高血压指南”，但实际上是在2011年发布的。在该指南中，所有五类抗高血压药物都被推荐作为可能的初始和维持治疗。治疗目标是收缩压/舒张压一般低于140/90 mm Hg，各组高风险患者为130/80 mm Hg，老年患者（≥65岁）为150/90 mm Hg。随着最近几个国家和国际高血压指南的出版，目前正在讨论更新中国指南。
According to the 4th National Nutrition and Health Survey in 2002, the prevalence of hypertension in China was 18.8%. Although there are no recent updated nationwide data, it is believed that the prevalence of hypertension has increased substantially in the past decade up to more than 200 million hypertensive patients in the populous country of China. To fight against the growing risk of hypertension, three Chinese hypertension guidelines were compiled in the past two decades, in 1999, 2005, and 2011. The current guidance document for the management of hypertension was named ‘2010 Chinese hypertension guideline', but it was actually published in 2011. In this guideline, all five classes of antihypertensive drugs were recommended as possible initial and maintenance therapy. The goal of treatment was a systolic/diastolic blood pressure below 140/90 mm Hg in general, 130/80 mm Hg in various groups of high-risk patients, and 150/90 mm Hg in the elderly (≥65 years). With the recent publication of several national and international hypertension guidelines, the Chinese guideline is now under discussion for updating.